Monday, March 17, 2025 | 12:59 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Hospitals charging over 500% for angioplasty devices: Maharashtra FDA

Report submitted to NPPA for action

graph
Premium

graph

Veena Mani New Delhi
The National Pharmaceutical Pricing Authority’s (NPPA’s) move to cap the price of cardiac stents has solved only half the problem faced by patients. Balloon and guiding catheters, essential devices in angioplasty, are still exorbitantly priced, a study conducted by the Maharashtra FDA (Food & Drug Administration) from December 2016 to April 2017 has shown. Business Standard has reviewed the report which has been submitted to the NPPA for action. 

In the supply chain, hospitals make the highest profits, the study reveals. For instance, balloon catheters are being sold by them at over four times the landed price by hospitals. Guiding

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in